Marina Berenguer
Marina Berenguer is an expert in Hepatology at Hospital Universitari i Politècnic La Fe (Spain). As of October 2026, ScienceLeadR ranks Marina Berenguer in the top 1% of experts worldwide for Liver Transplantation, Tissue Transplantation and Hepatitis. Marina Berenguer has authored 488 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 6 of them ongoing. SLR score: 1,929 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1995 - 2026
Number : 488
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Genetic testing and exchangeable copper can improve the accuracy of Wilson disease diagnoses. PMID 42758868 — liver diseases, research design, genetic testing, genetics, diagnosis, hepatolenticular degeneration, ceruloplasmin, neurology | Hepatol Commun | 2026 | 0 |
| Integrated multiomics analysis reveals metabolic and microbiome alterations in Wilson disease. PMID 42631006 — multiple chronic conditions, liver, hepatolenticular degeneration | iScience | 2026 | 0 |
| Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis. PMID 42329390 — liver diseases, diabetes mellitus, kidney diseases, hypertension, comorbidity, mortality, cholangitis, incidence, kidney, liver, prevalence, blood platelets, gastrointestinal diseases | J Gastroenterol | 2026 | 2 |
| Complete immunosuppression withdrawal after liver transplantation: An International Multicenter Study. PMID 42263796 — liver transplantation, mortality, fibrosis, tacrolimus, liver, calcineurin inhibitors, transplants, immunosuppression therapy, transplantation, weaning | Clin Gastroenterol Hepatol | 2026 | 0 |
| Reply to: Sex for the purposes of MELD 3.0 calculation: When this differs from birth sex and implications for policy. PMID 42118988 — liver diseases, parturition, sex | Hepatol Commun | 2026 | 0 |
Clinical Studies 15
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 7
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A randomised double blind placebo controlled two part study to evaluate the pharmacokinetics safety and tolerability and preliminary efficacy of two dose levels of golexanolone in subjects with primary biliary cholangitis fatigue and cognitive dysfunction 2024-515907-20-00 — cholangitis, safety, neurobehavioral manifestations, cognitive dysfunction, signs and symptoms, fatigue, therapeutics, pharmacokinetics | Phase 1/Phase 2 | Active not recruiting | 2022 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) 2025-522674-36-00 — liver diseases, liver | Phase 3 | Recruiting | 2026 |
| A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis 2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics | Phase 3 | Recruiting | 2024 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| LEOPARD Training and Validation Data Collection Study NCT06675604 — liver transplantation, mortality, cholangitis, liver cirrhosis, patient dropouts, data collection, liver, cholangitis, sclerosing, transplants, artificial intelligence, liver cirrhosis, biliary, transplantation, carcinoma | N/A | Recruiting | 2025 |
LeadR Networks
Main global connection map